Up to 80% of women will experience some form of cellulite (gynoid lipodystrophy). In addition, leading dermatologists believe that more than half of all women will experience moderate to severe cellulite. Many women have accepted the development of cellulite as inevitable and normal. However, this has not alleviated the distress and self-conscious feelings women encounter.

The biomolecular pathways that underlie the development of cellulite have not been completely elucidated. However, DermaGenoma is working with experts in the field to improve our understanding of cellulite pathogenesis for potential therapeutics.

There are currently a myriad of therapies available for the treatment of cellulite, most have limited, if any scientific evidence to their efficacy. However, identification of patients who are at a high risk for developing moderate to severe cellulite could allow early initiation of cellulite treatments when the odds of success are likely to be much higher. Existing therapies are unlikely to reverse severe cellulite once it has occurred; however, prior to the development of severe cellulite, lifestyle changes including exercise, medication choices (i.e. hormone-based birth control and hormone replacement therapy), and therapies, such as laser therapy, may slow or stop the development of severe cellulite and improve visual aesthetics.

In the past, physicians were unable to give patients a thorough assessment of their risk for developing moderate to severe cellulite. Currently, the CelluliteDX Genetic Test helps assess one’s risk for developing Nurnberger-Muller grade 2 (or greater) cellulite. In addition, those at a high risk for moderate to severe cellulite may benefit from various therapies and/or lifestyle changes. Furthermore, DermaGenoma is currently evaluating potential therapies for early stage cellulite based on genetic markers. By taking the test, your doctor will be able to determine if you are a good candidate for the latest genetic based therapies as they become available.

[back to top]